Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study

Risankizumab is a humanized IgG monoclonal antibody inhibitor of IL23 and has been recently approved by the EMA and the FDA for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Its efficacy and safety have been reported by clinical trials and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Megna, Matteo, Ruggiero, Angelo, Battista, Teresa, Marano, Laura, Cacciapuoti, Sara, Potestio, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179221/
https://www.ncbi.nlm.nih.gov/pubmed/37176672
http://dx.doi.org/10.3390/jcm12093233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179221/
https://www.ncbi.nlm.nih.gov/pubmed/37176672
http://dx.doi.org/10.3390/jcm12093233

Ejemplares similares